Compass Therapeutics (CMPX) Profit After Tax (2023 - 2025)
Historic Profit After Tax for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$14.3 million.
- Compass Therapeutics' Profit After Tax fell 3604.62% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.8 million, marking a year-over-year decrease of 3778.76%. This contributed to the annual value of -$49.4 million for FY2024, which is 1619.29% down from last year.
- Compass Therapeutics' Profit After Tax amounted to -$14.3 million in Q3 2025, which was down 3604.62% from -$19.9 million recorded in Q2 2025.
- Compass Therapeutics' Profit After Tax's 5-year high stood at -$7.8 million during Q1 2023, with a 5-year trough of -$19.9 million in Q2 2025.
- Over the past 3 years, Compass Therapeutics' median Profit After Tax value was -$13.1 million (recorded in 2024), while the average stood at -$13.0 million.
- As far as peak fluctuations go, Compass Therapeutics' Profit After Tax crashed by 518.87% in 2024, and later plummeted by 5419.49% in 2025.
- Over the past 3 years, Compass Therapeutics' Profit After Tax (Quarter) stood at -$13.4 million in 2023, then decreased by 12.06% to -$15.0 million in 2024, then grew by 5.15% to -$14.3 million in 2025.
- Its last three reported values are -$14.3 million in Q3 2025, -$19.9 million for Q2 2025, and -$16.6 million during Q1 2025.